Collaborator: Dana Farber Cancer Institute

• Actionable germline findings in endometrial cancer from a large multigene panel tested cohort

  Presenting Author: Adela Rodriguez Hernandez, MD at Dana-Farber Cancer Institute

  August 3, 2026

• Germline Pathogenic/Likely Pathogenic (P/LP) Variants in Epithelial Neuroendocrine Neoplasms: The Case for Universal Germline Genetic Testing

  Presenting Author: Udhayvir Singh Grewal, MD at Emory University

  August 3, 2026

• Germline Pathogenic Variants in Individuals with Renal Cell Carcinoma

  August 1, 2026

• Heterogeneity of pancreatic cancer risk across germline susceptibility genes and sex

  April 2, 2026

• Frequency and clinical features of germline pathogenic variants in sarcoma: A case-control study

• SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort

• A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome

• Time to testing for hereditary cancer: A comparison of age at cancer diagnosis and genetic testing

  Presenting Author: Magan Trottier, MS, CGC Take home points:  Significant Delays Exist Between Cancer Diagnosis and Genetic Testing: Across most cancer types, patients experience a lag of 2–4 years between diagnosis and hereditary cancer genetic testing. The longest delays were observed in ovarian (4.0 years) and kidney cancers (3.9 years), with particularly concerning delays for ovarian…

  April 2, 2026

• Benefits and Harms of Interception and Early Detection of Cancer

• Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception